Chronic Hepatitis B: A Critical Discussion

Jianfei Long,Min Wang,Bicui Chen,Jiming Zhang,Bin Wang
DOI: https://doi.org/10.2217/fvl-2016-0094
2017-01-01
Future Virology
Abstract:Telbivudine (LdT) is an antiviral agent currently used in the treatment of chronic hepatitis B virus, which was first approved by the US FDA in 2006. The safety of LdT is of great importance for patients that receive long-term treatment for this condition. It has been confirmed that patients treated with LdT have significantly elevated creatine kinase levels. However, the mechanism responsible for this adverse reaction is unclear. This review summarizes the current literature of the adverse reactions of LdT and the possible mechanisms that are involved in chronic hepatitis B infection. Thus, we aim to provide guidance on best practices in using LdT and to provide evidence of the possible mechanisms of LdT-associated adverse reactions.
What problem does this paper attempt to address?